Latest Us Expansion News

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

A volatile week for ASX tech saw a steep sell-off in freight software, while defence AI and RegTech contract wins pulled buyers back into smaller names. Big corporate actions kept attention on what’s real: signed deals, cash timelines, and who pays whom, and when.

American Tungsten & Antimony Ltd (ASX, AT4) has produced its first antimony ingots from its Utah project, validating its processing approach and advancing its US growth ambitions including a planned Nasdaq listing.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Xero Limited has outlined a bold AI strategy and detailed the integration of Melio to accelerate its US market growth, supported by new financial disclosures and a clear path to profitability.

Xero Limited reveals new AI product demonstrations and updates on Melio’s integration, reaffirming ambitious US growth and FY28 revenue targets.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Evion Group has bolstered its cash reserves to $2.3 million following a strategic placement and secured a $1.5 million expandable graphite sales agreement in the US, while advancing its Maniry Graphite Project in Madagascar with strong EU backing.

American Tungsten & Antimony Ltd (ASX, AT4) has initiated drilling at its Utah antimony project and expanded its Nevada tungsten portfolio, while preparing a spin-out IPO of Australian assets to sharpen its US focus.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.